International Oncology Services Private Limited Custom Case Solution & Analysis

International Oncology Services Private Limited: Executive Briefing

1. Evidence Brief (Researcher)

Financial Metrics:

• IOSPL revenue grew from INR 42 million (FY2009) to INR 145 million (FY2011).
• EBITDA margins: 12% (FY2009), 15% (FY2010), 18% (FY2011).
• Cost of medical equipment per center: INR 150 million to 200 million (Exhibit 4).
• Break-even point: Typically 30 months per center.

Operational Facts:

• Current network: 4 cancer centers across India (Exhibit 1).
• Business model: Partnership with existing hospitals (Asset-light, shared revenue).
• Staffing: Shortage of qualified oncologists and radiation therapists (Paragraph 14).

Stakeholder Positions:

• Prabhat Pant (CEO): Favors rapid expansion to capture first-mover advantage.
• Investors (Private Equity): Concerned about capital intensity and scalability.

Information Gaps:

• Detailed patient acquisition costs (CAC) per region.
• Specific attrition rates for medical staff.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question: How should IOSPL scale its network to achieve national dominance before larger hospital chains internalize oncology services?

Structural Analysis:

• Porter Five Forces: High buyer power (hospitals hold the real estate and patient flow). Supplier power (specialized medical talent) is extreme, creating a bottleneck.
• Value Chain: The primary value-add is the clinical protocol and equipment management, not the physical facility.

Strategic Options:

• Option 1: Aggressive Geographic Expansion. Open 10 new centers in 24 months. Trade-off: Dilutes management focus and strains talent pool. Resource: Requires external capital injection.
• Option 2: Focus on Hub-and-Spoke. Establish one high-end center in a Tier-1 city and satellite clinics in Tier-2/3. Trade-off: Lower margins per unit, but higher patient volume. Resource: Requires investment in logistics and telemedicine.
• Option 3: Strategic Consolidation. Partner exclusively with two major hospital chains. Trade-off: Limits geographic reach but secures revenue predictability. Resource: Requires high-level sales and relationship management.

Recommendation: Proceed with Option 2. It mitigates the talent shortage by centralizing specialized care in hubs while expanding reach through lower-cost satellites.

3. Implementation Roadmap (Operations Specialist)

Critical Path:

1. Month 1-3: Standardize the spoke clinic training module to allow non-oncologists to perform basic screenings.
2. Month 4-8: Identify and sign MoUs with 5 regional hospitals for satellite locations.
3. Month 9-12: Deploy telemedicine infrastructure connecting satellites to the central hub.

Key Constraints:

• Talent Scarcity: The model relies on remote supervision. If the central hub oncologists are overworked, the quality of care in satellites will collapse.
• Hospital Alignment: Partner hospitals may view IOSPL as an interim solution and eventually attempt to displace them.

Risk-Adjusted Strategy: Implement a mandatory rotation program where satellite staff spend one week per month at the central hub to maintain standards and clinical alignment.

4. Executive Review and BLUF (Executive Critic)

BLUF: IOSPL must pivot from a capital-heavy expansion model to a hub-and-spoke configuration. The current path of building full-scale centers in every market is unsustainable given the scarcity of specialized medical talent. By centralizing clinical expertise and decentralizing diagnostic screening, IOSPL can expand into Tier-2 markets at 40% lower capital cost per unit. This transition must be completed within 18 months to preempt hospital chains from building internal oncology departments. The business is currently a service provider; it must become a network operator to defend its margins.

Dangerous Assumption: The analysis assumes local hospital partners will remain passive. If a hospital partner sees the oncology unit generating 20% of their total facility revenue, they will move to renegotiate the revenue share or terminate the contract.

Unaddressed Risks:

• Regulatory: Changes in medical licensing laws for remote diagnosis could invalidate the hub-and-spoke model.
• Clinical Liability: A misdiagnosis at a remote satellite center carries brand-ending consequences for the entire network.

Unconsidered Alternative: A white-label consultancy model. Instead of owning the equipment, IOSPL could sell their clinical protocols and management expertise to hospitals for a flat fee and a smaller percentage of revenue, removing the capital burden entirely.

Verdict: APPROVED FOR LEADERSHIP REVIEW.